Classification criteria | Proportion of cases meeting criteria, % (95% CI) n1/n2, | |||
At time of diagnosis | 2 years after diagnosis* | At last visit in study period | ||
Adult-onset SLE | ||||
Total | 2019 EULAR/ACR | 91.6 (89.5–93.6) 642/701 | 92.7 (90.6–94.7) 568/613 | 94.0 (92.3–95.8) 659/701 |
1997 ACR | 77.3 (74.2–80.4) 542/701 | 82.5 (79.5–85.5) 506/613 | 84.3 (81.6–87.0) 591/701 | |
P<0.001 | P<0.001 | P<0.001 | ||
Female | 2019 EULAR/ACR | 92.5 (90.4–94.7) 546/590 | 93.6 (91.4–95.7) 480/513 | 94.6 (92.7–96.4) 558/590 |
1997 ACR | 79.0 (75.7–82.3) 466/590 | 83.6 (80.4–86.8) 429/513 | 85.6 (82.8–88.4) 505/590 | |
P<0.001 | P<0.001 | P<0.001 | ||
Male | 2019 EULAR/ACR | 86.5 (80.1–92.8) 96/111 | 88.0 (81.6–94.4) 88/100 | 91.0 (85.7–96.3) 101/111 |
1997 ACR | 68.5 (59.8–77.1) 76/111 | 77.0 (68.6–85.2) 77/100 | 77.5 (69.7–85.2) 86/111 | |
P<0.001 | P<0.05 | P<0.05 | ||
Juvenile-onset SLE‡ | ||||
Total | 2019 EULAR/ACR | 97.2 (91.9–102.6) 35/36 | 100 (100–100) 25/25 | 97.2 (91.9–102.6) 35/36 |
1997 ACR | 88.9 (78.6–99.2) 32/36 | 92.0 (81.4–102.6) 23/25 | 91.7 (82.6–100.7) 33/36 | |
Female | 2019 EULAR/ACR | 96.6 (89.9–103.1) 28/29 | 100 (100–100) 21/21 | 96.6 (89.9–103.2) 28/29 |
1997 ACR | 89.7 (78.5–100.7) 26/29 | 90.5 (77.9–102.6) 19/21 | 89.7 (78.6–100.7) 26/29 | |
Male | 2019 EULAR/ACR | 100† 7/7 | 100† 4/4 | 100† 7/7 |
1997 ACR | 85.7† 6/7 | 100† 4/4 | 100† 7/7 |
1997 ACR criteria, 1997 ACR classification criteria for SLE; 2019 EULAR/ACR criteria, 2019 EULAR/ACR classification criteria for SLE.
n1, number of cases fulfilling the criteria; n2,, total number of cases at visit
*Estimated sensitivity 2 years after diagnosis includes only the 638 incident cases during 2000–2015 to allow for 2-year follow-up for all cases.
†Less than 10 cases and to scarce for statistical analysis.
‡2019 EULAR/ACR criteria fulfilment vs 1997 ACR criteria fulfilment did not differ significantly.
EULAR/ACR, European Alliance of Associations for Rheumatology/American College of Rheumatology; SLE, systemic lupus erythematosus.